Incresed Risk for Mortality When Used For Longer Duration
An increased incidence of mortality was seen in TEMBEXAtreated subjects compared to placebo-treated subjects in a 24-week clinical trial when TEMBEXA was evaluated in another disease
Patient counseling
Package inserts
Keywords: Tembexa
Updated: July 2021
Disclaimer: This information presents a SUMMARY of Black Box data from product information labeling and does not address additional warnings, precautions, or other important safety data in the product insert. Patient care decisions SHOULD NOT be made without reviewing the most recent product information insert, which may be obtained from the manufacturer. This table may not be complete as it was prepared using product information from package inserts. It is periodically updated with supplemental information from FDA safety alerts, the FDA labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.